“Moderna and Merck Race Toward 2027 FDA Approval for Personalized Cancer Vaccine | Nova Glo” — what this page in the network covers. Moderna and Merck are accelerating toward a potential 2027 FDA submission for their personalized cancer vaccine, according to Moderna CEO Stéphane Bancel. The announcement came during the European Society for Medical Oncology (ESMO) conference, where the companies presented new data underscoring the The announcement came during the European Society for Medical Oncology (ESMO) conference, where the companies presented new data underscoring the therapy's promise in treating melanoma.
The vaccine, based on the same mRNA technology used in COVID-19 shots, is designed to prime the immune system against patient-specific tumor mutations. In clinical trials, combining the vaccine with Merck's Keytruda significantly reduced the risk of recurrence or death in high-risk melanoma patients. The companies are now planning a confirmatory Phase 3 trial to support regulatory approval. For the complete material, the listing points back to the source inside the network.